Literature DB >> 21210294

Progressive supranuclear palsy presenting with urinary retention and sleep apnea.

Fuyuki Tateno1, Ryuji Sakakibara, Masahiko Kishi, Tatsuhiko Yuasa, Emina Ogawa, Osamu Takahashi, Sayaka Yoshio, Megumi Sugiyama, Tomoyuki Uchiyama, Tatsuya Yamamoto, Tomonori Yamanishi.   

Abstract

We report a case of a 62-year-old Japanese-Australian woman with progressive supranuclear palsy (PSP) who presented with prominent urinary retention, neurogenic changes in sphincter electromyography, and obstructive sleep apnea syndrome. Urodynamic study revealed a combination of detrusor overactivity during filling and underactivity during voiding. All these non-motor symptoms in PSP mimicked those of multiple system atrophy.

Entities:  

Mesh：

Year:  2011        PMID： 21210294     DOI： 10.1007/s10286-010-0100-8

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN： 0959-9851            Impact factor:   4.435


  17 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

3.  Pontine pathology and voiding dysfunction.

Authors:  C D Betts; R Kapoor; C J Fowler
Journal:  Br J Urol       Date:  1992-07

4.  Neuronal loss in Onuf's nucleus in three patients with progressive supranuclear palsy.

Authors:  T Scaravilli; P P Pramstaller; A Salerno; E Egarter-Vigl; B Giometto; R Vitaliani; S F An; T Revesz
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

5.  The pathology of the spinal cord in progressive supranuclear palsy.

Authors:  Roberta Vitaliani; Tomaso Scaravilli; Eduard Egarter-Vigl; Bruno Giometto; Christine Klein; Francesco Scaravilli; Shu F An; Peter P Pramstaller
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

6.  Study of the rostral midbrain atrophy in progressive supranuclear palsy.

Authors:  Naoko Kato; Kimihito Arai; Takamichi Hattori
Journal:  J Neurol Sci       Date:  2003-06-15       Impact factor: 3.181

7.  Neurological diseases that cause detrusor hyperactivity with impaired contractile function.

Authors:  Tatsuya Yamamoto; Ryuji Sakakibara; Tomoyuki Uchiyama; Zhi Liu; Takashi Ito; Yusuke Awa; Tomonori Yamanishi; Takamichi Hattori
Journal:  Neurourol Urodyn       Date:  2006       Impact factor: 2.696

Review 8.  Sphincter EMG as a diagnostic tool in autonomic disorders.

Authors:  Ryuji Sakakibara; Tomoyuki Uchiyama; Tomonori Yamanishi; Masahiko Kishi
Journal:  Clin Auton Res       Date:  2008-09-08       Impact factor: 4.435

9.  [A case of progressive supranuclear palsy associated with bilateral vocal cord abductor paralysis].

Authors:  I Yokoji; S Nakamura; T Ikeda
Journal:  Rinsho Shinkeigaku       Date:  1997-06

Review 10.  The neural control of micturition.

Authors:  Clare J Fowler; Derek Griffiths; William C de Groat
Journal:  Nat Rev Neurosci       Date:  2008-06       Impact factor: 34.870
View more
  2 in total

Review 1.  Autonomic dysfunction in progressive supranuclear palsy.

Authors:  Francesca Baschieri; Maria Vitiello; Pietro Cortelli; Giovanna Calandra-Buonaura; Francesca Morgante
Journal:  J Neurol       Date:  2022-08-30       Impact factor: 6.682

2.  Urinary Dysfunction in Progressive Supranuclear Palsy Compared with Other Parkinsonian Disorders.

Authors:  Tatsuya Yamamoto; Fuyuki Tateno; Ryuji Sakakibara; Shogo Furukawa; Masato Asahina; Tomoyuki Uchiyama; Shigeki Hirano; Yoshitaka Yamanaka; Miki Fuse; Yasuko Koga; Mitsuru Yanagisawa; Satoshi Kuwabara
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.